{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:35:05Z","timestamp":1794900905804,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7928","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2022,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    On-target\u2013off-tissue drug engagement is an important source of adverse effects that constrains the therapeutic window of drug candidates\n                    <jats:sup>1,2<\/jats:sup>\n                    . In diseases of the central nervous system, drugs with brain-restricted pharmacology are highly desirable. Here we report a strategy to achieve inhibition of mammalian target of rapamycin (mTOR) while sparing mTOR activity elsewhere through the use of the brain-permeable mTOR inhibitor RapaLink-1 and the brain-impermeable FKBP12 ligand RapaBlock. We show that this drug combination mitigates the systemic effects of mTOR inhibitors but retains the efficacy of RapaLink-1 in glioblastoma xenografts. We further present a general method to design cell-permeable, FKBP12-dependent kinase inhibitors from known drug scaffolds. These inhibitors are sensitive to deactivation by RapaBlock, enabling the brain-restricted inhibition of their respective kinase targets.\n                  <\/jats:p>","DOI":"10.1038\/s41586-022-05213-y","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T12:03:00Z","timestamp":1663156980000},"page":"822-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Brain-restricted mTOR inhibition with binary pharmacology"],"prefix":"10.1038","volume":"609","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0541-7211","authenticated-orcid":false,"given":"Ziyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-4381","authenticated-orcid":false,"given":"Kevin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-9132","authenticated-orcid":false,"given":"William A.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-7741","authenticated-orcid":false,"given":"Kevan M.","family":"Shokat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"5213_CR1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.taap.2004.04.010","volume":"200","author":"TE Johnson","year":"2004","unstructured":"Johnson, T. E. et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol. Appl. Pharmacol. 200, 237\u2013250 (2004).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"5213_CR2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0306-4522(94)90178-3","volume":"59","author":"PB Reiner","year":"1994","unstructured":"Reiner, P. B. & Kamondi, A. Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current. Neuroscience 59, 579\u2013588 (1994).","journal-title":"Neuroscience"},{"key":"5213_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"M Li","year":"2019","unstructured":"Li, M. et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J. Rare Dis. 14, 1\u20139 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"5213_CR4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"DN Franz","year":"2006","unstructured":"Franz, D. N. et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490\u2013498 (2006).","journal-title":"Ann. Neurol."},{"key":"5213_CR5","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1021\/acs.jmedchem.8b01262","volume":"61","author":"D Rageot","year":"2018","unstructured":"Rageot, D. et al. Discovery and preclinical characterization of 5-[4,6-bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1\/2 inhibitor for cancer and neurological disorders. J. Med. Chem. 61, 10084\u201310105 (2018).","journal-title":"J. Med. Chem."},{"key":"5213_CR6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/neuonc\/noq052","volume":"12","author":"D Akhavan","year":"2010","unstructured":"Akhavan, D., Cloughesy, T. F. & Mischel, P. S. Learned from bench to bedside. Neuro Oncol. 12, 882\u2013889 (2010).","journal-title":"Neuro Oncol."},{"key":"5213_CR7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","volume":"31","author":"QW Fan","year":"2017","unstructured":"Fan, Q. W. et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. Cancer Cell 31, 424\u2013435 (2017).","journal-title":"Cancer Cell"},{"key":"5213_CR8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10637-019-00875-4","volume":"38","author":"S Lapointe","year":"2020","unstructured":"Lapointe, S. et al. A phase I study of vistusertib (dual mTORC1\/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. Invest. New Drugs 38, 1137\u20131144 (2020).","journal-title":"Invest. New Drugs"},{"key":"5213_CR9","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04774952 (2022)."},{"key":"5213_CR10","doi-asserted-by":"crossref","first-page":"20093","DOI":"10.1073\/pnas.1005554107","volume":"107","author":"J Neasta","year":"2010","unstructured":"Neasta, J. et al. Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. Proc. Natl Acad. Sci. USA 107, 20093\u201320098 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5213_CR11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nn.3439","volume":"16","author":"S Barak","year":"2013","unstructured":"Barak, S. et al. Disruption of alcohol-related memories by mTORC1 inhibition prevents relapse. Nat. Neurosci. 16, 1111\u20131117 (2013).","journal-title":"Nat. Neurosci."},{"key":"5213_CR12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/adb.12528","volume":"23","author":"N Morisot","year":"2018","unstructured":"Morisot, N., Novotny, C. J., Shokat, K. M. & Ron, D. A new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice. Addict. Biol. 23, 713\u2013722 (2018).","journal-title":"Addict. Biol."},{"key":"5213_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14740338.2013.752814","volume":"12","author":"N Pallet","year":"2013","unstructured":"Pallet, N. & Legendre, C. Adverse events associated with mTOR inhibitors. Expert Opin. Drug Saf. 12, 177\u2013186 (2013).","journal-title":"Expert Opin. Drug Saf."},{"key":"5213_CR14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00467-011-1811-3","volume":"26","author":"D Gonz\u00e1lez","year":"2011","unstructured":"Gonz\u00e1lez, D. et al. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr. Nephrol. 26, 961\u2013966 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"5213_CR15","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1073\/pnas.91.26.12574","volume":"91","author":"MI Chiu","year":"1994","unstructured":"Chiu, M. I., Katz, H. & Berlin, V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12\/rapamycin complex. Proc. Natl Acad. Sci. USA 91, 12574\u201312578 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5213_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","volume":"10","author":"R Loewith","year":"2002","unstructured":"Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457\u2013468 (2002).","journal-title":"Mol. Cell"},{"key":"5213_CR17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molcel.2015.04.031","volume":"58","author":"C Gaubitz","year":"2015","unstructured":"Gaubitz, C. et al. Molecular basis of the rapamycin insensitivity of target of rapamycin complex 2. Mol. Cell 58, 977\u2013988 (2015).","journal-title":"Mol. Cell"},{"key":"5213_CR18","doi-asserted-by":"crossref","first-page":"0371-0383","DOI":"10.1371\/journal.pbio.1000038","volume":"7","author":"ME Feldman","year":"2009","unstructured":"Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, 0371-0383 (2009).","journal-title":"PLoS Biol."},{"key":"5213_CR19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20090489","volume":"421","author":"JM Garc\u00eda-Mart\u00ednez","year":"2009","unstructured":"Garc\u00eda-Mart\u00ednez, J. M. et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29\u201342 (2009).","journal-title":"Biochem. J."},{"key":"5213_CR20","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","volume":"284","author":"CC Thoreen","year":"2009","unstructured":"Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023\u20138032 (2009).","journal-title":"J. Biol. Chem."},{"key":"5213_CR21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","volume":"534","author":"VS Rodrik-Outmezguine","year":"2016","unstructured":"Rodrik-Outmezguine, V. S. et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534, 272\u2013276 (2016).","journal-title":"Nature"},{"key":"5213_CR22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1073\/pnas.0805375106","volume":"106","author":"PS Marinec","year":"2009","unstructured":"Marinec, P. S. et al. FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo. Proc. Natl Acad. Sci. USA 106, 1336\u20131341 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5213_CR23","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.7554\/eLife.00105","volume":"2","author":"DE Orange","year":"2013","unstructured":"Orange, D. E. et al. Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo. eLife 2, e00105 (2013).","journal-title":"eLife"},{"key":"5213_CR24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu, J. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66, 807\u2013815 (1991).","journal-title":"Cell"},{"key":"5213_CR25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0092-8674(95)90439-5","volume":"82","author":"JP Griffith","year":"1995","unstructured":"Griffith, J. P. et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82, 507\u2013522 (1995).","journal-title":"Cell"},{"key":"5213_CR26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","volume":"369","author":"EJ Brown","year":"1994","unstructured":"Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756\u2013758 (1994).","journal-title":"Nature"},{"key":"5213_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","volume":"78","author":"DM Sabatini","year":"1994","unstructured":"Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35\u201343 (1994).","journal-title":"Cell"},{"key":"5213_CR28","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.1021\/ja00075a008","volume":"115","author":"DA Holt","year":"1993","unstructured":"Holt, D. A. et al. Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands. J. Am. Chem. Soc. 115, 9925\u20139938 (1993).","journal-title":"J. Am. Chem. Soc."},{"key":"5213_CR29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cell.2006.07.025","volume":"126","author":"LA Banaszynski","year":"2006","unstructured":"Banaszynski, L. A., Chen, L. C., Maynard-Smith, L. A., Ooi, A. G. & Wandless, T. J. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995\u20131004 (2006).","journal-title":"Cell"},{"key":"5213_CR30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541\u2013553 (2005).","journal-title":"NeuroRx"},{"key":"5213_CR31","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1021\/jm501535r","volume":"58","author":"Z Rankovic","year":"2015","unstructured":"Rankovic, Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J. Med. Chem. 58, 2584\u20132608 (2015).","journal-title":"J. Med. Chem."},{"key":"5213_CR32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1074-5521(02)00085-6","volume":"9","author":"PA Clemons","year":"2002","unstructured":"Clemons, P. A. et al. Synthesis of calcineurin-resistant derivatives of FK506 and selection of compensatory receptors. Chem. Biol. 9, 49\u201361 (2002).","journal-title":"Chem. Biol."},{"key":"5213_CR33","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/cbic.200800806","volume":"10","author":"C Kozany","year":"2009","unstructured":"Kozany, C., M\u00e4rz, A., Kress, C. & Hausch, F. Fluorescent probes to characterise FK506-binding proteins. ChemBioChem 10, 1402\u20131410 (2009).","journal-title":"ChemBioChem"},{"key":"5213_CR34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4049\/jimmunol.144.1.251","volume":"144","author":"FJ Dumont","year":"1990","unstructured":"Dumont, F. J., Staruch, M. J., Koprak, S. L., Melino, M. R. & Sigal, N. H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144, 251\u2013258 (1990).","journal-title":"J. Immunol."},{"key":"5213_CR35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24567-x","volume":"12","author":"Y Ehinger","year":"2021","unstructured":"Ehinger, Y. et al. Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice. Nat. Commun. 12, 4407 (2021).","journal-title":"Nat. Commun."},{"key":"5213_CR36","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/1078-0432.CCR-05-2510","volume":"12","author":"JN Sarkaria","year":"2006","unstructured":"Sarkaria, J. N. et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 12, 2264\u20132271 (2006).","journal-title":"Clin. Cancer Res."},{"key":"5213_CR37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1021\/jm401654j","volume":"57","author":"AA Estrada","year":"2014","unstructured":"Estrada, A. A. et al. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 57, 921\u2013936 (2014).","journal-title":"J. Med. Chem."},{"key":"5213_CR38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tips.2012.04.001","volume":"33","author":"BD Lee","year":"2012","unstructured":"Lee, B. D., Dawson, V. L. & Dawson, T. M. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson\u2019s disease. Trends Pharmacol. Sci. 33, 365\u2013373 (2012).","journal-title":"Trends Pharmacol. Sci."},{"key":"5213_CR39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1741-7015-10-20","volume":"10","author":"IN Rudenko","year":"2012","unstructured":"Rudenko, I. N., Chia, R. & Cookson, M. R. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson\u2019s disease? BMC Med. 10, 20 (2012).","journal-title":"BMC Med."},{"key":"5213_CR40","first-page":"273ra15","volume":"7","author":"RN Fuji","year":"2015","unstructured":"Fuji, R. N. et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl. Med. 7, 273ra15 (2015).","journal-title":"Sci. Transl. Med."},{"key":"5213_CR41","doi-asserted-by":"crossref","first-page":"eaav0820","DOI":"10.1126\/scitranslmed.aav0820","volume":"12","author":"MAS Baptista","year":"2020","unstructured":"Baptista, M. A. S. et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci. Transl. Med. 12, eaav0820 (2020).","journal-title":"Sci. Transl. Med."},{"key":"5213_CR42","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo, L. J. et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658\u20136661 (2004).","journal-title":"J. Med. Chem."},{"key":"5213_CR43","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/neuonc\/nov011","volume":"17","author":"AB Lassman","year":"2015","unstructured":"Lassman, A. B. et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 17, 992\u2013998 (2015).","journal-title":"Neuro Oncol."},{"key":"5213_CR44","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","volume":"30","author":"PJ Medina","year":"2008","unstructured":"Medina, P. J. & Goodin, S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 30, 1426\u20131447 (2008).","journal-title":"Clin. Ther."},{"key":"5213_CR45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-009-1041-6","volume":"65","author":"B Thiessen","year":"2010","unstructured":"Thiessen, B. et al. A phase I\/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother. Pharmacol. 65, 353\u2013361 (2010).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"5213_CR46","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.chembiol.2019.10.005","volume":"26","author":"PH Bos","year":"2019","unstructured":"Bos, P. H. et al. Development of MAP4 kinase inhibitors as motor neuron-protecting agents. Cell Chem. Biol. 26, 1703\u20131715.e37 (2019).","journal-title":"Cell Chem. Biol."},{"key":"5213_CR47","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/jacs.6b08536","volume":"139","author":"Q Zhao","year":"2017","unstructured":"Zhao, Q. et al. Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes. J. Am. Chem. Soc. 139, 680\u2013685 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"5213_CR48","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/215852b0","volume":"215","author":"G Bartholini","year":"1967","unstructured":"Bartholini, G., Burkard, W. P., Pletscher, A. & Bates, H. M. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215, 852\u2013853 (1967).","journal-title":"Nature"},{"key":"5213_CR49","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/jcp.24324","volume":"228","author":"BS Komm","year":"2013","unstructured":"Komm, B. S. & Mirkin, S. Evolution of the tissue selective estrogen complex (TSEC). J. Cell. Physiol. 228, 1423\u20131427 (2013).","journal-title":"J. Cell. Physiol."},{"key":"5213_CR50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s13311-016-0511-x","volume":"14","author":"TN Chase","year":"2017","unstructured":"Chase, T. N., Farlow, M. R. & Clarence-Smith, K. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer\u2019s disease. Neurotherapeutics 14, 405\u2013416 (2017).","journal-title":"Neurotherapeutics"},{"key":"5213_CR51","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.19760","volume":"5","author":"Max A Horlbeck","year":"2016","unstructured":"Horlbeck, M. A. et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. eLife 5, e19760 (2016).","journal-title":"eLife"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05213-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05213-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05213-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T22:09:52Z","timestamp":1676758192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05213-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":51,"journal-issue":{"issue":"7928","published-print":{"date-parts":[[2022,9,22]]}},"alternative-id":["5213"],"URL":"https:\/\/doi.org\/10.1038\/s41586-022-05213-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742323584.793596791","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.742323584.793596314","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.12.336677","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-92256\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.Z., Q.F., W.A.W. and K.M.S. are co-inventors on patent applications covering RapaBlock owned by UCSF. K.M.S. is an inventor on patents covering RapaLink-1 owned by UCSF and licensed to Revolution Medicines. K.M.S. receives monetary and stock compensation and is an SAB member of Genentech\/Roche,\u00a0Denali Therapeutics and Revolution Medicines. Kin of K.L. hold stock in and are employed by Pharmaron.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}